Overview
Acumen Q3 net income and income from operations beat analyst estimates
Company's cash expected to support operations into early 2027
R&D expenses decreased due to reduced CRO costs for ALTITUDE-AD trial
Outlook
Company expects topline results from ALTITUDE-AD study in late 2026
Company anticipates non-clinical data to inform EBD strategy in early 2026
Cash reserves expected to support operations into early 2027
Result Drivers
R&D EXPENSES - Decrease in R&D expenses attributed to reduced CRO costs for ALTITUDE-AD trial
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | Beat | -$26.45 mln | -$35.46 mln (4 Analysts) |
Q3 Income From Operations | Beat | -$26.51 mln | -$33.83 mln (4 Analysts) |
Q3 Basic EPS | -$0.44 | ||
Q3 Operating Expenses | $26.51 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $9.50, about 79.3% above its November 11 closing price of $1.97
Press Release: ID:nGNX52ymd9
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)